Advanced Accelerator Applications

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Advanced Accelerator Applications sits in the upper quartile of US sponsors by registered trial count (#1,604 of 15,742 sponsors by registered trial count).

8 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Advanced Accelerator Applications: 8 sponsored US clinical trials, none currently recruiting.

Advanced Accelerator Applications sponsors 8 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Gastroenteropancreatic Neuroendocrine Tumors, with 1 trials.

Upper-quartile sponsor footprint

Advanced Accelerator Applications sits in the upper quartile of the sponsor corpus (#1,604 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

8 total, page 1 of 1

ACTIVE NOT RECRUITING Phase 2

Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

NCT04711135
ACTIVE NOT RECRUITING Phase 3

Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET

NCT03972488
ACTIVE NOT RECRUITING

Post-Authorization Long-Term Safety Study of LUTATHERA

NCT03691064
COMPLETED Phase 1

[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-neoB Lesion Uptake

NCT03872778
TERMINATED Phase 1

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

NCT03490838
COMPLETED Phase 1

68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)

NCT03490032
TERMINATED Phase 2

99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis

NCT03232580
COMPLETED Phase 3

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

NCT01578239

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 2
Phase 3 2

Therapeutic Areas

Gastroenteropancreatic Neuroendocrine Tumors 1
Neuroendocrine Tumors 1
Pheochromocytoma 1
Paraganglioma 1
Neoplasms 1
Gastroenteropancreatic Neuroendocrine Tumor 1

How the Advanced Accelerator Applications early-phase archive is shaped

8 indexed studies, none listed as recruiting (0% open); 3 completed (38%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Gastroenteropancreatic Neuroendocrine Tumors (1 trial), 5 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Advanced Accelerator Applications: archived-pipeline peers nationwide

Peers matched on 8 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Advanced Accelerator Applications sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Advanced Accelerator ApplicationsAB ScienceAbbott Point of CareAbeona TherapeuticsAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10xBio22nd Century Group23andMe3-C Institute for Social Development
Advanced Accelerator Applications sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Advanced Accelerator Applications sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 8 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Advanced Accelerator Applications page

8 registered trials is a research-attention snapshot, not an endorsement of Advanced Accelerator Applications or any single study.

  • None of Advanced Accelerator Applications's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Gastroenteropancreatic Neuroendocrine Tumors is the condition Advanced Accelerator Applications studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Gastroenteropancreatic Neuroendocrine Tumors trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Advanced Accelerator Applications pipeline card: 8 registered trials from official public datasets.Report a data error.